First Parkinson’s Patient Dosed with IkT-148009 in Phase 1 Trial
The first Parkinson’s patient has been dosed in a Phase 1 clinical trial that is testing IkT-148009, an investigational oral therapy being developed by Inhibikase Therapeutics to slow or stop disease progression. “We are pleased to begin dosing patients in our Phase 1b study,” Milton Werner, PhD,…